PAREDRINE (hydroxyamphetamine hydrobromide) by PhotoPharmics is clinical pharmacology paremyd solution combines the effects of the adrenergic agent, hydroxyamphetamine hydrobromide, and the anticholinergic agent, tropicamide. First approved in 1969.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
PAREDRINE (hydroxyamphetamine hydrobromide) is a topical ophthalmic solution combining an indirectly-acting sympathomimetic agent with tropicamide to produce mydriasis (pupil dilation) and partial cycloplegia. It facilitates ophthalmoscopic examination by causing pupil dilation and diminished light responsiveness within 15 minutes of instillation. The drug works by releasing endogenous norepinephrine from adrenergic nerve terminals while blocking cholinergic responses in the iris and ciliary muscles.
Product approaching loss of exclusivity with minimal linked opportunities; commercial team likely focused on retention and cost management rather than expansion.
CLINICAL PHARMACOLOGY PAREMYD Solution combines the effects of the adrenergic agent, hydroxyamphetamine hydrobromide, and the anticholinergic agent, tropicamide. Hydroxyamphetamine hydrobromide is an indirectly-acting sympathomimetic agent which, when applied topically to the eye, causes the…
Worked on PAREDRINE at PhotoPharmics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PAREDRINE offers limited career growth prospects given its LOE-approaching status and minimal job openings (0 linked roles). Roles are primarily defensive—managing declining sales, maintaining compliance, and planning transition strategies rather than driving innovation or market expansion.